CBCC Global Research welcomes Okogen CEO, Joshua Moriarty, to our most recent episode of the Around the Globe Webinar Series. Listen in to learn more about recent updates and the #innovation that Okogen is moving forward.

Rosanne Michie of Optometry Austrialia reviews Okogen’s upcoming Australian trial that aims to fill the absence of approved therapies to treat the underlying cause of viral conjunctivitis.

In this article from Mommybites, Francis Mah, MD discusses the causes of pink eye, common symptoms, prevention tips, steps you can take for home treatment and when to seek the help of an eye care specialist.

Okogen innovates a novel treatment for a common and often serious ophthalmic condition with no approved therapies. Hear the phrase “pink eye” and more than likely you immediately picture red, runny, painful eyes. You might even feel your own eyes

The San Diego Union Tribune covers Okogen’s receival of $10 million in Series A funding to further invest in treatments for viral conjunctivitis.

OKG-0301 is a novel ribonuclease that can enter host cells and preferentially degrade viral tRNA leading to an inhibition of protein synthesis. This is an evaluation of the anti-adenoviral efficacy of topical OKG-0301 in the Ad5/NZW rabbit ocular model.

This article from Review of Ophthamology is a discussion of the various causes of conjunctivitis, and new therapeutic approaches on the horizon.